zinc finger protein 736 pseudogene 4, Y-linkedGenealiases: []
Q-omics provides the consensus-scored ZNF736P4Y profile across patient tissues and cancer cell-line models. ZNF736P4Y expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, ZNF736P4Y is differentially expressed in 2, with the highest sampling consensus in KIRP. Additionally, ZNF736P4Y RNA expression shows 1,302 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight DLBC, KIRP, and KIRC as cancer lineages where ZNF736P4Y shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF736P4Y — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF736P4Y survival associations across molecular data types. ZNF736P4Y RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF736P4Y RNA expression–survival associations across cancer types. High ZNF736P4Y expression shows unfavorable associations in DLBC, KIRC, STAD, CHOL, KIRP and LIHC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify DLBC as the clearest survival context for ZNF736P4Y RNA expression.
This table summarizes ZNF736P4Y tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF736P4Y. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF736P4Y shows lower tumor expression in KIRP and KICH. The KIRP box plot shows higher ZNF736P4Y RNA expression in normal versus tumor tissue (log2 FC = −0.104, t-test p < 0.001).
This table shows molecular features associated with ZNF736P4Y in patient tissues and cancer cell lines. In patient samples, ZNF736P4Y shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
